Brief introduction of response evaluation criteria in solid tumors

doi:10.3760/cma.j.issn.1673-422X.2016.11.011

Abstract

Abstract: With the coming era of targeted therapy, novel criteria such as the modified response evaluation criteria in solid tumors (RECIST), positron emission tomography response criteria in solid tumors (PETRCIST), Choi criteria and immunerelated response criteria have been proposed as standardized methods to assess therapeutic response. Biomarkers and circulating tumor cells may be considered suitable for the evaluation of response. These criteria may be useful for the evaluation of therapeutic response to tumors.

Key words: Neoplasms, Durg evaluation, Response evaluation criteria, Molecular targeted therapy

Zhang Baihong, Yue Hongyun. Brief introduction of response evaluation criteria in solid tumors[J]. Journal of International Oncology, 2016, 43(11): 845-847.

References

［1］ Hewitt SM, Badve SS, True LD, et al. Impact of preanalytic factors on the design and application of integral biomarkers for directing patient therapy［J］. Clin Cancer Res, 2012, 18(6): 1524-1530. DOI: 10.1158/1078-0432.CCR-11-2204. ［2］ Sharma MR, Maitland ML, Ratain MJ. RECIST: no longer the sharpest tool in the oncology clinical trials toolboxpoint［J］. Cancer Res, 2012, 72(20): 5145-5149. DOI: 10.1158/0008-5472.CAN-12-0058. ［3］ Lencioni R. New data supporting modified RECIST (mRECIST) for hepatocellular carcinoma［J］. Clin Cancer Res, 2013, 19(6): 1312-1314. DOI: 10.1158/1078-0432.CCR-12-3796. ［4］ Kim BK, Kim KA, Park JY, et al. Prospective comparison of prognostic values of modified response evaluation criteria in solid tumours with European association for the study of the liver criteria in hepatocellular carcinoma following chemoembolisation［J］. Eur J Cancer, 2013, 49(4): 826-834. DOI: 10.1016/j.ejca.2012.08.022. ［5］ Bargellini I, Scionti A, Mismas V, et al. Identification of responders to sorafenib in hepatocellular carcinoma: is tumor volume measurement the way forward?［J］. Oncology, 2014, 86(4): 191-198. DOI: 10.1159/000358599. ［6］ Taieb S, SaadaBouzid E, Tresch E, et al. Comparison of response evaluation criteria in solid tumours and Choi criteria for response evaluation in patients with advanced soft tissue sarcoma treated with trabectedin: a retrospective analysis［J］. Eur J Cancer, 2015, 51(2): 202-209. DOI: 10.1016/j.ejca.2014.11.008. ［7］ Ding Q, Cheng X, Yang L, et al. PET/CT evaluation of response to chemotherapy in nonsmall cell lung cancer: PET response criteria in solid tumors (PERCIST) versus response evaluation criteria in solid tumors (RECIST)［J］. J Thorac Dis, 2014, 6(6): 677-683. DOI: 10.3978/j.issn.2072-1439.2014.05.10. ［8］ Skougaard K, Johannesen HH, Nielsen D, et al. CT versus FDGPET/CT response evaluation in patients with metastatic colorectal cancer treated with irinotecan and cetuximab［J］. Cancer Med, 2014, 3(5): 1294-1301. DOI: 10.1002/cam4.271. ［9］ Ziai D, Wagner T, El Badaoui A, et al. Therapy response evaluation with FDGPET/CT in small cell lung cancer: a prognostic and comparison study of the PERCIST and EORTC criteria［J］. Cancer Imaging, 2013, 13: 73-80. DOI: 10.1102/1470-7330.2013.0008. ［10］ Stacchiotti S, Verderio P, Messina A, et al. Tumor response assessment by modified Choi criteria in localized highrisk soft tissue sarcoma treated with chemotherapy［J］. Cancer, 2012, 118(23): 5857-5866. DOI: 10.1002/cncr.27624. ［11］ Schmidt N, Hess V, Zumbrunn T, et al. Choi response criteria for prediction of survival in patients with metastatic renal cell carcinoma treated with anti-angiogenic therapies［J］. Eur Radiol, 2013, 23(3): 632-639. DOI: 10.1007/s00330-012-2640-x. ［12］ Ronot M, Bouattour M, Wassermann J, et al. Alternative response criteria (Choi, European association for the study of the liver, and modified response evaluation criteria in solid tumors ［RECIST］) versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib［J］. Oncologist, 2014, 19(4): 394-402. DOI: 10.1634/theoncologist.2013-0114. ［13］ Kim HS, Kim JW, Kim JH, et al. Singlelesion measurement per organ for assessing tumor response in advanced gastric cancer［J］. Oncology, 2015, 88(2): 69-75. DOI: 10.1159/000367810. ［14］ Nishino M, Gargano M, Suda M, et al. Optimizing immunerelated tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab?［J］. J Immunother Cancer, 2014, 2: 17. DOI: 10.1186/2051-1426-2-17. ［15］ Enooku K, Tateishi R, Kanai F, et al. Evaluation of molecular targeted cancer drug by changes in tumor marker doubling times［J］. J Gastroenterol, 2012, 47(1): 71-78. DOI: 10.1007/s00535011-0462-2. ［16］ Alexandre J, Brown C, Coeffic D, et al. CA125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial［J］. Br J Cancer, 2012, 106(4): 633-637. DOI: 10.1038/bjc.2011.593. ［17］ Tsuchiya K, Asahina Y, Matsuda S, et al. Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma［J］. Cancer, 2014, 120(2): 229-237. DOI: 10.1002/cncr.28384. ［18］ Abusaif S, Jradi Z, Held L, et al. S100B and lactate dehydrogenase as response and progression markers during treatment with vemurafenib in patients with advanced melanoma［J］. Melanoma Res, 2013, 23(5): 396-401. DOI: 10.1097/CMR.0b013e3283650741. ［19］ Vishnukumar S, Umamaheswaran G, Anichavezhi D, et al. Pglycoprotein expression as a predictor of response to neoadjuvant chemotherapy in breast cancer［J］. Indian J Cancer, 2013, 50(3): 195-199. DOI: 10.4103/0019-509X.118726. ［20］ Punnoose EA, Atwal S, Liu W, et al. Evaluation of circulating tumor cells and circulating tumor DNA in nonsmall cell lung cancer: association with clinical endpoints in a phase Ⅱ clinical trial of pertuzumab and erlotinib［J］. Clin Cancer Res, 2012, 18(8): 2391-2401. DOI: 10.1158/1078-0432.CCR-11-3148. ［21］ Wallwiener M, Riethdorf S, Hartkopf AD, et al. Serial enumeration of circulating tumor cells predicts treatment response and prognosis in metastatic breast cancer: a prospective study in 393 patients［J］. BMC Cancer, 2014, 14: 512. DOI: 10.1186/1471-2407-14-512. ［22］ Najjar F, Alammar M, Bachour M, et al. Predictive and prognostic value of circulating endothelial cells in nonsmall cell lung cancer patients treated with standard chemotherapy［J］. J Cancer Res Clin Oncol, 2015, 141(1): 119-125. DOI: 10.1007/s00432-014-1778-0. ［23］ Teng FF, Meng X, Sun XD, et al. New strategy for monitoring targeted therapy: molecular imaging［J］. Int J Nanomedicine, 2013, 8: 3703-3713. DOI: 10.2147/IJN.S51264.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying. Research progress of habitat analysis in radiomics of malignant tumors [J]. Journal of International Oncology, 2024, 51(5): 292-297.